Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Tilray Brands Inc (TLRY) Price & Performance

Rex Fang & Innovation Equity Premium Income ETFTrade
Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

Rex Fang & Innovation Equity Premium Income ETF vs Tilray Brands Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.82, while Tilray Brands Inc trades at $4.38 (market cap $541.36M). The key difference: Rex Fang & Innovation Equity Premium Income ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.

FEPITLRY
Sector
Income / Options OverlayHealth
52-Week High
$49.54$21.00
52-Week Low
$38.13$4.31
Market Cap
$541.36M
Enterprise Value
$638.50M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rex Fang & Innovation Equity Premium Income ETF

FEPI trades at $41.76, down 1.6% today, with a bearish technical signal from moving averages. The ETF generates high income through weekly covered call distributions, recently transitioning to weekly payouts. Recent dividends show consistent payments around $0.20-$0.22 per share, with one larger $0.90 distribution in April 2026. The concentrated portfolio of AI and mega-cap tech names provides QQQ-like exposure but with capped upside from call writing.

The outlook remains cautious due to NAV erosion risks from the covered call strategy limiting participation in rallies. While the 25% yield attracts income seekers, total returns have lagged broader tech indices. Key risks include high portfolio concentration and market volatility impacting premium income generation. Analyst views are mixed, balancing high yield against structural limitations.

Tilray Brands Inc

TLRY trades at $4.355, down 0.57% on the day, amid a bearish technical signal and weak earnings performance. The company reported a net loss of $2.19 billion in 2025, with a negative net income margin of -156.67%, while revenue grew to $821.31 million. Recent news includes medical cannabis expansion in Panama and the acquisition of HelloMD to enhance digital healthcare capabilities.

The outlook remains challenging due to persistent losses and high debt levels, though low valuation ratios like P/S of 0.55 and P/B of 0.35 may attract value investors. Key risks include profitability struggles, regulatory uncertainty, and competitive pressures in the cannabis sector. Analyst sentiment is mixed, with 65% hold ratings reflecting caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Rex Fang & Innovation Equity Premium Income ETF

FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.

Read more on FEPI

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY